Aptus Pharma FY26 results: revenue doubles to Rs. 4,670.81 Lakhs
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 28 Apr 2026, 08:06 PM IST · BSE ID: 602b5ffb-4e0b-4895-9e44-cf61e1d85eb3
View Original BSE Filing (PDF)
💡
In Simple Terms
Aptus Pharma's sales doubled this year to Rs. 4,670.81 Lakhs, but profit growth lagged at 49% due to margin pressure.
🤖 AI Summary
- FY26 total revenue doubled to Rs. 4,670.81 Lakhs, up 89.59% YoY from Rs. 2,463.64 Lakhs
- Net profit grew 49.05% YoY to Rs. 461.99 Lakhs; EBITDA increased 57.73% to Rs. 750.32 Lakhs
- EBITDA margin compressed to 16.06% from 19.31%; PAT margin fell to 9.89% from 12.58%
- Portfolio expanded to 250+ formulations; distribution network covers 25,000+ retail outlets via 200+ distributors
- Company operates via asset-light model with WHO-GMP certified manufacturing partners; targets pan-India presence by 2030
🔢 Key Numbers — exact figures from BSE filing, not rounded
Total Revenue FY26
Rs. 4,670.81 Lakhs
89.59%
Net Profit (PAT) FY26
Rs. 461.99 Lakhs
49.05%
EBITDA FY26
Rs. 750.32 Lakhs
57.73%
EBITDA Margin FY26
16.06%
-325 bps
PAT Margin FY26
9.89%
-269 bps
Product Portfolio
250+ formulations
Retail Distribution Network
25,000+ outlets
🏢 How This Affects the Company
Revenue expansion to Rs. 4,670.81 Lakhs with portfolio now spanning 250+ formulations across Rx, OTC, global export, and ORBIT franchise channels demonstrates scaling across multiple verticals. Distribution footprint of 25,000+ retail outlets and 10,000+ doctors supports market penetration roadmap toward national presence by 2030.
While revenue doubled 89.59% YoY, net profit growth of 49.05% and EBITDA growth of 57.73% signal operational leverage is not yet translating proportionally to bottom line. EBITDA margin contraction from 19.31% to 16.06% and PAT margin decline from 12.58% to 9.89% indicate cost pressures or pricing competition are eroding profitability despite scale.
Asset-light manufacturing model via WHO-GMP certified partners enables rapid formulation launches and portfolio expansion without capex burden. Franchise-led ORBIT model is accelerating market penetration into underpenetrated regions, broadening operational reach beyond core Rx and OTC channels.
Margin compression despite strong revenue growth raises questions about unit economics and pricing sustainability. Dependence on multiple manufacturing partners creates supply chain concentration risk. High growth phase may strain working capital and distribution logistics if not carefully managed.
👥 What This Means For Shareholders
✅
Action Required
Review FY27 Q1 results when filed to confirm whether margin decline stabilizes or continues; track capex announcements on manufacturing expansion.
👤
Who Is Affected
All equity shareholders. Growth-stage investors benefit from revenue expansion; value investors face uncertainty from margin deterioration. EPS dilution from margin compression affects earnings-based valuations.
🔍
Management Signal
Aggressive expansion prioritized over profitability optimization. Franchise model (ORBIT) and multi-vertical strategy indicate willingness to accept margin pressure for market share and footprint growth.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q1 FY27 results — verify if EBITDA margin stabilizes above 16% or erodes further
Manufacturing capex announcements — track in-house production facility plans to improve margin control
ORBIT franchise expansion metrics — monitor new franchisees added and their contribution to revenue growth
MEDIUM RISK
Margin compression despite revenue doubling signals operational challenges. Asset-light model creates supply chain risk. SME listing limits liquidity and analyst coverage.
💡 Investor Takeaway
FY26 revenue doubled to Rs. 4,670.81 Lakhs (89.59% YoY), but net profit grew only 49.05% to Rs. 461.99 Lakhs. Margin compression from 19.31% to 16.06% EBITDA margin suggests cost pressures outpacing pricing power despite 250+ portfolio and 25,000+ retail distribution.
⚖️ Strengths & Concerns
✅ Positives
- Revenue doubled YoY to Rs. 4,670.81 Lakhs with 89.59% growth rate and 250+ product portfolio
- Diversified distribution: 25,000+ retail outlets, 200+ distributors, 10,000+ doctor relationships provide market reach
⚠️ Concerns
- EBITDA margin fell 325 basis points from 19.31% to 16.06%; PAT margin down 269 basis points to 9.89%
- Profit growth of 49.05% significantly trails revenue growth of 89.59%, indicating operational leverage deterioration
📅 Company Track Record
Company incorporated 2010 (CIN U24230GJ2010PLC061957). Established as local player, now scaling regionally with 250+ portfolio. BSE SME listing provides capital access but limited public disclosure history pre-2026. No prior quarterly filing data available to assess margin trend sustainability.
Based on publicly available historical data. For context only.